WO1997044449A1 - Promoteurs d'inhibiteurs complementaires porcins - Google Patents
Promoteurs d'inhibiteurs complementaires porcins Download PDFInfo
- Publication number
- WO1997044449A1 WO1997044449A1 PCT/JP1997/001677 JP9701677W WO9744449A1 WO 1997044449 A1 WO1997044449 A1 WO 1997044449A1 JP 9701677 W JP9701677 W JP 9701677W WO 9744449 A1 WO9744449 A1 WO 9744449A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- promoter
- pmcp
- human
- dna
- complement inhibitors
- Prior art date
Links
- 241000282898 Sus scrofa Species 0.000 title abstract description 37
- 239000004074 complement inhibitor Substances 0.000 title abstract description 36
- 239000002773 nucleotide Substances 0.000 claims description 20
- 125000003729 nucleotide group Chemical group 0.000 claims description 20
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 6
- 235000012745 brilliant blue FCF Nutrition 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 42
- 241000282414 Homo sapiens Species 0.000 abstract description 41
- 108020004414 DNA Proteins 0.000 abstract description 39
- 210000000056 organ Anatomy 0.000 abstract description 18
- 238000011144 upstream manufacturing Methods 0.000 abstract description 9
- 230000009261 transgenic effect Effects 0.000 abstract description 8
- 238000002054 transplantation Methods 0.000 abstract description 7
- 102000012607 Thrombomodulin Human genes 0.000 abstract description 4
- 108010079274 Thrombomodulin Proteins 0.000 abstract description 4
- 208000007536 Thrombosis Diseases 0.000 abstract description 4
- 230000015572 biosynthetic process Effects 0.000 abstract description 4
- 230000002401 inhibitory effect Effects 0.000 abstract description 3
- 238000010276 construction Methods 0.000 abstract description 2
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 29
- 229940124073 Complement inhibitor Drugs 0.000 description 22
- 210000004027 cell Anatomy 0.000 description 20
- 108090000623 proteins and genes Proteins 0.000 description 18
- 101100386242 Homo sapiens CD55 gene Proteins 0.000 description 15
- 239000002299 complementary DNA Substances 0.000 description 13
- 238000009396 hybridization Methods 0.000 description 13
- 230000000295 complement effect Effects 0.000 description 12
- 239000000243 solution Substances 0.000 description 12
- 241000282412 Homo Species 0.000 description 10
- 108060001084 Luciferase Proteins 0.000 description 10
- 108091008146 restriction endonucleases Proteins 0.000 description 10
- 210000003556 vascular endothelial cell Anatomy 0.000 description 10
- 241000282887 Suidae Species 0.000 description 9
- 238000000034 method Methods 0.000 description 9
- 239000000523 sample Substances 0.000 description 9
- 239000005089 Luciferase Substances 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 102100039373 Membrane cofactor protein Human genes 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- 101100297347 Caenorhabditis elegans pgl-3 gene Proteins 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 238000003776 cleavage reaction Methods 0.000 description 4
- 230000024203 complement activation Effects 0.000 description 4
- 238000007796 conventional method Methods 0.000 description 4
- 229940088598 enzyme Drugs 0.000 description 4
- 239000012634 fragment Substances 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 239000013612 plasmid Substances 0.000 description 4
- 230000007017 scission Effects 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 238000002689 xenotransplantation Methods 0.000 description 4
- 241000588724 Escherichia coli Species 0.000 description 3
- 230000023555 blood coagulation Effects 0.000 description 3
- 239000013592 cell lysate Substances 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 108010073385 Fibrin Proteins 0.000 description 2
- 102000009123 Fibrin Human genes 0.000 description 2
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 2
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
- 101000961414 Homo sapiens Membrane cofactor protein Proteins 0.000 description 2
- 108090000190 Thrombin Proteins 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 229950003499 fibrin Drugs 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 238000010353 genetic engineering Methods 0.000 description 2
- 229960003444 immunosuppressant agent Drugs 0.000 description 2
- 239000003018 immunosuppressive agent Substances 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 229960004072 thrombin Drugs 0.000 description 2
- HBZBAMXERPYTFS-SECBINFHSA-N (4S)-2-(6,7-dihydro-5H-pyrrolo[3,2-f][1,3]benzothiazol-2-yl)-4,5-dihydro-1,3-thiazole-4-carboxylic acid Chemical compound OC(=O)[C@H]1CSC(=N1)c1nc2cc3CCNc3cc2s1 HBZBAMXERPYTFS-SECBINFHSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 241000972773 Aulopiformes Species 0.000 description 1
- 102100022002 CD59 glycoprotein Human genes 0.000 description 1
- 101100459438 Caenorhabditis elegans nac-1 gene Proteins 0.000 description 1
- 102100025680 Complement decay-accelerating factor Human genes 0.000 description 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
- 108010036949 Cyclosporine Proteins 0.000 description 1
- 102000004594 DNA Polymerase I Human genes 0.000 description 1
- 108010017826 DNA Polymerase I Proteins 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 241000283074 Equus asinus Species 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 101000897400 Homo sapiens CD59 glycoprotein Proteins 0.000 description 1
- 101000856022 Homo sapiens Complement decay-accelerating factor Proteins 0.000 description 1
- 101001128634 Homo sapiens NADH dehydrogenase [ubiquinone] 1 beta subcomplex subunit 2, mitochondrial Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 101710146216 Membrane cofactor protein Proteins 0.000 description 1
- 102100032194 NADH dehydrogenase [ubiquinone] 1 beta subcomplex subunit 2, mitochondrial Human genes 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 241000282579 Pan Species 0.000 description 1
- 241000282520 Papio Species 0.000 description 1
- 241001504519 Papio ursinus Species 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 108700005075 Regulator Genes Proteins 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 235000010724 Wisteria floribunda Nutrition 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 210000001557 animal structure Anatomy 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 230000007969 cellular immunity Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229960001265 ciclosporin Drugs 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000004154 complement system Effects 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 229930182912 cyclosporin Natural products 0.000 description 1
- 239000007857 degradation product Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 238000001400 expression cloning Methods 0.000 description 1
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 1
- PGBHMTALBVVCIT-VCIWKGPPSA-N framycetin Chemical compound N[C@@H]1[C@@H](O)[C@H](O)[C@H](CN)O[C@@H]1O[C@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](N)C[C@@H](N)[C@@H]2O)O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CN)O2)N)O[C@@H]1CO PGBHMTALBVVCIT-VCIWKGPPSA-N 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 102000044446 human CD46 Human genes 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 230000001338 necrotic effect Effects 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 229940053050 neomycin sulfate Drugs 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 230000008816 organ damage Effects 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000002601 radiography Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 235000019515 salmon Nutrition 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 238000002791 soaking Methods 0.000 description 1
- JUJBNYBVVQSIOU-UHFFFAOYSA-M sodium;4-[2-(4-iodophenyl)-3-(4-nitrophenyl)tetrazol-2-ium-5-yl]benzene-1,3-disulfonate Chemical compound [Na+].C1=CC([N+](=O)[O-])=CC=C1N1[N+](C=2C=CC(I)=CC=2)=NC(C=2C(=CC(=CC=2)S([O-])(=O)=O)S([O-])(=O)=O)=N1 JUJBNYBVVQSIOU-UHFFFAOYSA-M 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/472—Complement proteins, e.g. anaphylatoxin, C3a, C5a
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/108—Swine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/02—Animal zootechnically ameliorated
- A01K2267/025—Animal producing cells or organs for transplantation
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
Definitions
- the present invention relates to DNA having a specific nucleotide sequence, and more particularly, to a promoter of porcine complement inhibitor.
- organ transplantation has been widely performed in various countries, and the rejection of organ transplantation from human to human has been resolved by the development of particularly excellent immunosuppressants (cyclosporine, FK506, etc.). .
- immunosuppressants cyclosporine, FK506, etc.
- donors transplantation of animal organs into humans, that is, xenotransplantation, has been studied.
- xenotransplantation For example, in Europe and the United States, about 350 heart transplants are performed annually, but at present, this number is only about 20 to 30% of patients who need heart transplants.
- DAF Decay accelating factor
- MCP Membrane cofactor protein
- CD59 Three important complement inhibitors are DAF (Decay accelating factor, CD55), MCP (Membrane cofactor protein, CD46), and CD59. DAF and MCP are thought to inhibit the activation of complement by inhibiting the C9 step by increasing the breakdown of C3b and C3ZC5 convertases.
- Complement inhibitors are species-specific, and porcine complement inhibitors can block porcine complement activity but not human complement activity. Therefore, when pig tissue is transplanted into a human and the human complement system is activated, it cannot be suppressed by a pig complement inhibitor. As a result, pig tissues transplanted into humans will be necrotic.
- complement inhibitors Factors (hereinafter collectively referred to as complement inhibitors) may be expressed in advance.
- the complement inhibitor of human may be expressed in advance in pig vascular endothelial cells.
- transgenic pigs transgenic pigs
- human complement inhibitor genes From this point of view, studies on transgenic pigs (transgenic pigs) incorporating human complement inhibitor genes have been actively conducted.
- factors that can control the blood coagulation system reaction may be usefully expressed in pig organs alone or in advance together with human complement inhibitors using genetic engineering methods.
- transgenic pigs incorporating a human complement inhibitor As described above, xenotransplantation using transgenic pigs incorporating a human complement inhibitor has been studied.
- the promoter used in the production of this transgenic pig is derived from a human complement inhibitor or from a virus.
- the promoter of complement inhibitors derived from pigs may be more effective.
- the present inventors have further studied and obtained the genomic DNA of pMCP from the porcine genomic library using the above cDNA of pMCP as a probe, and identified the promoter region of pMCP from the genomic DNA. And its base sequence was successfully determined.
- the pMCP promoter of the present invention was derived from pMCP genomic DNA, and the pMCP genomic DNA was selected using the pMCP cDNA.
- the pMCP cDNA is derived from RNA in porcine vascular endothelial cells. That is, the promoter of pMCP of the present invention functions as a regulatory gene when pMCP is expressed in pig vascular endothelial cells.
- the complement inhibitor gene of human can be used in pig organs, especially in pig. It can be expressed in vascular endothelial cells.
- the use of the pMCP promoter of the present invention enables efficient, selective and specific expression of various structural genes in porcine organs, particularly porcine vascular endothelial cells.
- the present invention has been made based on such findings, and an object of the present invention is to provide a DNA having one promoter activity of pMCP. Disclosure of the invention
- the present invention relates to a nucleotide sequence represented by SEQ ID NO: 1 or a DN sequence comprising a part of the nucleotide sequence or a DN sequence comprising the nucleotide sequence.
- another invention of the present invention relates to about 4 lkb, 2.4 kb, 1.7 kb, 0.9 kb, 0.5 kb, 0.5 kb, 0.5 kb, 0.9 kb, 0.5 kb, 0.5 kb, 0.5 kb, 0.5 kb, 0.5 kb, 0.5 kb, 0.5 kb, 0.5 kb, 0.5 kb, 0.5 kb, 0.5 kb, 0.5 kb, 0.5 kb, 0.5 kb, 0.5 kb, 0.5 kb, 0.5 kb, 0.5 kb, 0.5 kb, 0.5 kb, 0.5 kb, 0.5 kb, 0.5 kb, 0.5 kb, 0.5 kb, 0.5 kb, 0.5 kb, 0.5 kb, 0.5 kb, 0.5 kb, 0.5 kb, 0.5 kb, 0.5 k
- FIG. 1 shows the promoter activity of each promoter region.
- FIG. 2 is a diagram showing a comparison between the promoter activity of the promoter of the present invention and the promoter activity of the hDAF promoter.
- the base sequence shown in SEQ ID NO: 1 according to the present invention is a DNA having pMCP promoter activity.
- the DNA for example, obtain the genomic DNA of the pMCP structural gene from one of the commercially available puta genomic libraries, identify the promoter region present upstream of the genomic DNA, and cut out with an appropriate restriction enzyme. It can be obtained by:
- the genomic DNA of the pMCP structural gene is obtained by using pMCP cDNA or a part thereof as a probe, and porcine genomic library by a conventional black hybridization method or colony hybridization method.
- This can be done by cloning.
- the plaque hybridization method (1) using a swine genomic phage library, phage clones and Escherichia coli are cultured on an agar plate to form plaques; (2) replicating the plaques on a nitrocellulose filter; The phage DNA in the plaque was fixed on the filter; 3 Hybridization was performed using the aforementioned pMCP cDNA probe labeled with a radioisotope, etc., and the filter was removed. Radiography By removing the plaque, plaques of the phage containing the desired pMCP genomic DNA are detected. By repeating this operation, a phage containing the genomic DNA of pMCP can be cloned.
- phage clones containing a genomic DNA having a promoter region were selected.Because the promoter region is considered to have the first exon, the phage clone was selected from the first exon of the already known human pMCP cDNA. A region considered to be equivalent can be excised from pMCP cDNA, and using this as a probe, plaque hybridization is performed in the same manner as described above, and positive clones are selected.
- the genomic DNA of MCP can be obtained.
- the DNA of the promoter region of pMCP is obtained by cutting the upstream region of the genomic DNA of pMCP obtained above with an appropriate restriction enzyme, testing the promoter activity of the obtained DNA fragment, and extracting the active fragment. It can be obtained by sampling.
- the test of the promoter activity can be performed according to a conventional method. For example, a fragment digested with a restriction enzyme is incorporated into a vector for measuring the activity of solesiferase, the vector is introduced into appropriate cells, the cells are cultured for a predetermined time, and the cells are lysed.
- the promoter activity can be tested by measuring the luciferase activity of E. coli.
- the promoter region of the pMCP genomic gene was obtained from the pig genomic library by the method described above, a promoter region of approximately 5400 bp was obtained, as shown in the Examples below. .
- sequence of the nucleotide sequence in this region was determined according to a conventional method, it was revealed that the nucleotide sequence had the nucleotide sequence shown in SEQ ID NO: 1 (5418 bases).
- this promoter region was cleaved with an appropriate restriction enzyme, and the promoter activity was tested by the test method described above. As a result, strong promoter activity was observed up to about 1700 bp upstream. Then, when the sequence of the nucleotide sequence of about 1700 bp was determined according to a conventional method, it was revealed that the nucleotide sequence had the nucleotide sequence shown in SEQ ID NO: 2 (1622 nucleotides).
- the DNA of the present invention may be a part of the nucleotide sequence shown in SEQ ID NO: 1 or may contain the nucleotide sequence shown in SEQ ID NO: 1 as long as it has pMCP promoter activity. .
- the DNA of the present invention can be used not only as a promoter of pMCP but also as a promoter of expression of various structural genes, in which case, depending on the structural gene, cell type, animal species, etc. to be expressed.
- a product having good promoter activity can be appropriately selected from a full-length sequence.
- the thus obtained DNA of the present invention has a promoter activity for a structural gene such as pMCP and can be used for various purposes.
- a structural gene such as pMCP
- the transgenic pig when producing a transgenic pig into which a human complement inhibitor has been incorporated, the transgenic pig is incorporated upstream of the human complement inhibitor and used to effectively generate a human complement inhibitor.
- complement inhibitors can be expressed in pig vascular endothelial cells.
- the DNA of the present invention can also be used as a promoter for expression of various structural genes other than pMCP.
- the DNA of the present invention is not limited to those obtained in the above examples, but also includes those obtained by other methods. Further, as long as the DNA of the present invention has a promoter activity, some bases of the base sequence may be substituted or deleted, and one or more bases may be inserted. Industrial applicability
- the DNA of the present invention is a promoter of pMCP, and is used to produce human complement by upstream integration of the human complement inhibitor when producing a transgenic pig incorporating the human complement inhibitor.
- Inhibitors can be effectively expressed. Therefore, it is possible to prevent hyperacute rejection that occurs when pig tissues and organs are transplanted into humans, so that xenotransplantation of pig tissues and organs into humans becomes possible, and there is a shortage of donors for organ transplants. This has the effect of solving the problem.
- the pMCP genome was obtained by using FIXII butagen phage library 1 (Stratagene) as a genome library, and using full length pMC Pc DNA obtained by expression cloning as a probe (Xh0I , Not I) and plaque hybridization. The outline of the method is shown below.
- this filter was mixed with a buffer for prehybridization [50% deionized formamide, x4 SSC, 50m HEPES (pH7), xlO Denhardt solution, 100mg / ml denatured salmon sperm DNA] at 37 ° C. Incubate for 4 hours to block.
- a buffer for prehybridization 50% deionized formamide, x4 SSC, 50m HEPES (pH7), xlO Denhardt solution, 100mg / ml denatured salmon sperm DNA
- the probe performs the label is reacted with a radioisotope the plasmid [a- 32 P] d NT P and K 1 Enow in the presence ATP (DNA polymerase I).
- a radioisotope the plasmid [a- 32 P] d NT P and K 1 Enow in the presence ATP (DNA polymerase I).
- the cDNA is transformed into type II, and the reverse strand of the cDNA incorporating the radioisotope is formed, and this reverse strand can bind to a phage clone having the same DNA sequence as type III.
- the labeled probe is passed through a gel filtration spin column to remove unreacted radioisotope-labeled nucleotides, incubated at 90 ° C for 3 minutes, and cooled on ice to make the DNA single-stranded. Used for hybridization in this state. ,
- the pre-hybridized filter was placed in a hybrid pack containing a pre-hybridization buffer to which the probe was added, and
- this filter is washed twice with an appropriate concentration of SSC: and SDS solutions, reacted with an image analyzer plate for 2 hours at room temperature, and analyzed with an image analyzer (manufactured by FUJI FILM).
- a plaque gel corresponding to this positive clone was sucked with a pasteur pit and diluted with SM buffer to obtain a clone solution.
- the above-mentioned clone solution was diluted with 1 plate of each clone (total of 30 plates) so that each plaque was separated and appeared sufficiently, and hybridization was performed again. As a result, many positive plaques appeared in 20 plates. Thus, 20 positive clones were obtained.
- each clone was cut with a restriction enzyme Ec0RI and then run on a gel.
- the clones were classified according to the difference in the cleavage pattern, and 10 types of clones were obtained.
- the clone containing the promoter region is considered to have the first exon, so that the human MCP c A region presumed to correspond to the first exon of DNA was cut out (Sa1I-SphI), and hybridization was performed using this as a probe. As a result, four clones were positive.
- the FspI present in the first exon was excised with a combination of FspI and another enzyme (Ec0RI) so as to be located at the end, and the sequence vector pBSIIKS10 (Stratagene) was used. ) And sequenced (373 DNA sequencer, Applied Biosystems).
- this clone certainly contained the sequence of the first exon.
- the present phage clone contained about 13 kbp of a genomic sequence in the upstream region considered to be the promoter region of pMCP as a whole, based on the restriction enzyme cleavage pattern of the phage clone.
- the activity of the promoter region was examined using a system utilizing the gene for the enzyme luciferase.
- the approximately 5.4 kbp promoter region of pMCP (13 kbp contained in the phage clone was too large to use for construct construction, so the one cut at the Ec0RI site in the middle was used)
- a region containing a T7 primer recognition sequence upstream thereof was excised from the plasmid used in the above sequence with the restriction enzyme BstEII-BssHII.
- the sequence of the nucleotide sequence in the region of the promoter of about 5.4 kbp was determined according to a conventional method, and it was revealed that the promoter had the nucleotide sequence shown in SEQ ID NO: 1 (54 18 bases).
- the above-mentioned promoter region was flattened with T4 DNA polymerase at its ends and subcloned into the Sma I site of pGL-3 basic vector (Proniega), a vector for measuring luciferase activity. did.
- the vector for measuring luciferase activity described above does not have a promoter region, but incorporates a promoter whose promoter activity is to be measured into the luciferase gene, and the activity of the promoter region depends on the activity of the luciferase enzyme. Is to see the strength of The activity of this luciferase enzyme lyses cells, obtains a cell lysate containing this enzyme, and reacts this solution with the enzyme substrate. ⁇ Q
- TAKARA TAKARA
- a pGL_3 vector with a promoter region of 5 kb in length was constructed.
- a pGL-3 vector having the SV40 promoter was obtained in the same manner using the SV40 promoter.
- the above-described promoter region of about 5.4 kb was ligated in the reverse direction to the vector, and the promoter of human DAF (hDAF) (about 4 kb) was ligated to the vector. Things were made.
- the luciferase activity was measured using a primary cultured cell line derived from pig vascular endothelial cells.
- the cultured pig cell line was detached with trypsin ZEDT A, washed, and then suspended in a HeBS buffer so as to have 3 ⁇ 10 6 cells / 800 ⁇ l.
- the above cells were cultured, collected after 48 hours, washed well with PBS, added with a cell lysate, and allowed to react at room temperature for 10 minutes. 10 ⁇ l of the obtained cell lysate was mixed with luciferase substrate solution 501, and the fluorescence of the solution was measured using a Luininescense Reader (AL0RA).
- Figure 1 shows the results. The numerical values were corrected in terms of 1 X 1 0 5 per viable cell. In addition, the activity was shown as a relative activity with the activity of pGL-3 vector having the SV40 promoter as a control being 100. In Fig. 1, -5.4 kb is the reverse of ligation of a 5.4 kb open-motor region to the vector. Means a 10-d promoter coupled to a vector.
- the sequence was performed using the T7 primer-recognition sequence located upstream of one region of the promoter of each length created by the deletion mutant using the diprimer method. Each sequence was performed twice, and the unreadable part was subcloned into pBS IKS + and the T3 primer recognition sequence was used.
- the electroporation was performed using a Genetrainer (registered trademark, manufactured by Bio Rad) under the conditions of 00 ⁇ F, 300V.
- the cells were cultured in a culture solution containing 250 / ig / ml neomycin sulfate (manufactured by Gibco), and cells forming colonies were collected.
- Cell surface hDAF expression is biotinylated.
- Anti-hDAF monoclonal antibodies IA10, IIH6 and VIIIA7; Kinoshita, T., et. Al. (1 985) After staining with J. Exp. Med. 162: 75) and Streptavidin-PE (manufactured by Biomeda), measurement was performed by FAC Scan (manufactured by Becton Dickinson).
- FIG. 2 shows a part of the comparison test results of each promoter and the expression level of hDAF.
- FL2-H on the horizontal axis in FIG. 2 indicates the expression level of hDAF, and the more the shift to the right, the higher the expression level.
- the count on the vertical axis in FIG. 2 represents the number of cells, and the higher the number, the higher the number of cells.
- Each graph is a graph for the promoter shown at the bottom, the black peak indicates the response to FACScan of cells that did not react with the antibody, and the white peak was reacted with the hDAF antibody 4 shows the response of cells to FACS Ca ⁇ . As a result, hDAF expression was not observed without the promoter.
- the expression of all pMCP promoters was more than 20 times higher than that of the hDAF promoter. That is, the promoter of about 5.4 kb, 1.7 kb and 0.9 kb effectively expresses human complement inhibitor in the swine vascular endothelial cell line by the reaction with the specific antibody. was confirmed.
- Sequence type nucleic acid
- TTCTCCCCTA ATCTCCCAAA ATATGGGCAA AGGACAGGTA CCCGTGGCAC 500 TGGAAAAATA CAGGCAAGCA ACCCATGAGT ACATGAAAAG ATGCTCCAGG 550
- n c_n en n CCCCC GGGAGAAAA TGGCCAAACCCGTGATGAAATTA TAGCG TTTTT TGA
- Array length 1 6 2 2
- Sequence type nucleic acid
- TTCCTTTTGC TAATCATACA GGCTTACTCA
- CCAGGCAGTC TGCAGTGCCC CAGTCCCCAC CAGAGCCCTG AAGGGTGTCG 1 100 GGCCCCACGA AACCGCTGCC CGGGCTCTAG GGTTTCTGTT TTCAGGTCGC 1 150 ⁇
- V03VIIIDX3 DVOV030DID I13DV0VIII 30I0IDV030
Landscapes
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Plant Pathology (AREA)
- Veterinary Medicine (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Description
Claims
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/180,939 US6255474B1 (en) | 1996-05-17 | 1997-05-19 | Promoters for swine complement inhibitors |
AT97922097T ATE314466T1 (de) | 1996-05-17 | 1997-05-19 | Promotoren von komplementinhibitoren des schweines. |
CA002254889A CA2254889C (en) | 1996-05-17 | 1997-05-19 | A promoter gene for a porcine complement inhibitor |
AU27904/97A AU2790497A (en) | 1996-05-17 | 1997-05-19 | Promoters for swine complement inhibitors |
EP97922097A EP0940467B1 (en) | 1996-05-17 | 1997-05-19 | Promoters for swine complement inhibitors |
DE69734999T DE69734999T2 (de) | 1996-05-17 | 1997-05-19 | Promotoren von komplementinhibitoren des schweines. |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP14833596 | 1996-05-17 | ||
JP8/148335 | 1996-05-17 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1997044449A1 true WO1997044449A1 (fr) | 1997-11-27 |
Family
ID=15450472
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP1997/001677 WO1997044449A1 (fr) | 1996-05-17 | 1997-05-19 | Promoteurs d'inhibiteurs complementaires porcins |
Country Status (6)
Country | Link |
---|---|
US (1) | US6255474B1 (ja) |
EP (1) | EP0940467B1 (ja) |
AT (1) | ATE314466T1 (ja) |
AU (1) | AU2790497A (ja) |
DE (1) | DE69734999T2 (ja) |
WO (1) | WO1997044449A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002015681A1 (fr) * | 2000-08-25 | 2002-02-28 | Nippon Meat Packers, Inc. | Mammiferes transgeniques |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999003336A1 (fr) * | 1997-07-14 | 1999-01-28 | Nippon Meat Packers, Inc. | Mammiferes transgeniques |
US20060148080A1 (en) * | 2004-12-30 | 2006-07-06 | Paul Diamond | Methods for supporting and producing human cells and tissues in non-human mammal hosts |
US20060147429A1 (en) * | 2004-12-30 | 2006-07-06 | Paul Diamond | Facilitated cellular reconstitution of organs and tissues |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997000951A1 (fr) * | 1995-06-20 | 1997-01-09 | Nippon Meat Packers, Inc. | Adn codant pour un inhibiteur du complement, d'origine porcine |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6166288A (en) * | 1995-09-27 | 2000-12-26 | Nextran Inc. | Method of producing transgenic animals for xenotransplantation expressing both an enzyme masking or reducing the level of the gal epitope and a complement inhibitor |
-
1997
- 1997-05-19 EP EP97922097A patent/EP0940467B1/en not_active Expired - Lifetime
- 1997-05-19 AU AU27904/97A patent/AU2790497A/en not_active Abandoned
- 1997-05-19 WO PCT/JP1997/001677 patent/WO1997044449A1/ja active IP Right Grant
- 1997-05-19 AT AT97922097T patent/ATE314466T1/de not_active IP Right Cessation
- 1997-05-19 US US09/180,939 patent/US6255474B1/en not_active Expired - Fee Related
- 1997-05-19 DE DE69734999T patent/DE69734999T2/de not_active Expired - Fee Related
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997000951A1 (fr) * | 1995-06-20 | 1997-01-09 | Nippon Meat Packers, Inc. | Adn codant pour un inhibiteur du complement, d'origine porcine |
Non-Patent Citations (2)
Title |
---|
MAMMALIAN GENOME, (1996), No. 7, A.K. WINTERO et al., "Evaluation and Characterization of a Porcine Small Intestine cDNA Library: Analysis of 839 Clones", pages 509-517. * |
TRANSPLANTATION PROCEEDINGS, (1995), Vol. 27, No. 1, F.H. BACH et al., "Xenotransplantation: Endothelial Cell Activation and Beyond", pages 77-79. * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002015681A1 (fr) * | 2000-08-25 | 2002-02-28 | Nippon Meat Packers, Inc. | Mammiferes transgeniques |
US7485769B2 (en) | 2000-08-25 | 2009-02-03 | Nippon Meat Packers, Inc. | Transgenic mammals |
Also Published As
Publication number | Publication date |
---|---|
US6255474B1 (en) | 2001-07-03 |
DE69734999T2 (de) | 2006-09-21 |
EP0940467A4 (en) | 2000-12-20 |
AU2790497A (en) | 1997-12-09 |
ATE314466T1 (de) | 2006-01-15 |
DE69734999D1 (de) | 2006-02-02 |
EP0940467B1 (en) | 2005-12-28 |
EP0940467A1 (en) | 1999-09-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2019216699B2 (en) | Site-Specific Enzymes and Methods of Use | |
Tu et al. | Embryonic and hematopoietic stem cells express a novel SH2–containing inositol 5′-phosphatase isoform that partners with the Grb2 adapter protein | |
JPH05504467A (ja) | Abo遺伝子型 | |
EP1071471A2 (en) | Methods and vector constructs for making transgenic non-human animals which ubiquitously express a heterologous gene | |
JPH07132088A (ja) | ウシ胚の性の識別方法 | |
US5705732A (en) | Universal donor cells | |
WO1997044449A1 (fr) | Promoteurs d'inhibiteurs complementaires porcins | |
WO2019173248A1 (en) | Engineered nucleic acid-targeting nucleic acids | |
JPH06503953A (ja) | Dna、dna構造体、細胞及びこれらから誘導した植物 | |
EP0710250A1 (en) | Human mhc class ii double transgene and uses | |
US6455037B1 (en) | Cells expressing an αgala nucleic acid and methods of xenotransplantation | |
US5750825A (en) | Mouse with defective endotheline-1 gene function | |
Sémat et al. | Sequence analysis of murine cytokeratin endo A (n° 8) cDNA. Evidence for mRNA species initiated upstream of the normal 5′ end in PCC4 cells | |
Tazaki et al. | The body margin of the planarian Dugesia japonica: characterization by the expression of an intermediate filament gene | |
CA2271228A1 (en) | Method for producing tagged genes, transcripts and proteins | |
JP3897858B2 (ja) | ブタ補体インヒビターのプロモーター | |
US7449562B2 (en) | PERV screening method and use thereof | |
Skynner et al. | Transgenic mice ubiquitously expressing Human Placental Alkaline Phosphatase (PLAP): an additional reporter gene for use in tandem with�-galactosidase (lacZ) | |
CN112979822A (zh) | 一种疾病动物模型的构建方法及融合蛋白 | |
JP4749541B2 (ja) | レスポンダー表現型に関わる核酸およびその適用 | |
CA2196190A1 (en) | Ikaros transgenic cells and animals | |
CN113666998B (zh) | 一种具有调控神经系统发育功能的PTEN亚型蛋白PTENδ及其应用 | |
AU782459B2 (en) | Promoters for swine complement inhibitors | |
CN107557386B (zh) | 促进人多能干细胞异种嵌合的方法 | |
JP2005528084A (ja) | 生存可能なc−kit発現細胞を単離するための道具 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AU CA US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
ENP | Entry into the national phase |
Ref document number: 2254889 Country of ref document: CA Ref country code: CA Ref document number: 2254889 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: 09180939 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1997922097 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1997922097 Country of ref document: EP |
|
WWG | Wipo information: grant in national office |
Ref document number: 1997922097 Country of ref document: EP |